Circulating levels of soluble receptor for advanced glycation end products and ligands of the receptor for advanced glycation end products in patients with acute liver failure

Giuseppina Basta, Serena Del Turco, Teresa Navarra, William M. Lee, Acute Liver Failure Study Group – 30 March 2015 – Animal studies suggest that receptor for advanced glycation end products (RAGE)–dependent mechanisms contribute to acetaminophen‐induced liver damage.

Percutaneous yttrium aluminum garnet–laser lithotripsy of intrahepatic stones and casts after liver transplantation

Nis Hallundbæk Schlesinger, Peter Svenningsen, Susanne Frevert, André Wettergren, Jens Hillingsø – 30 March 2015 – Bile duct stones and casts (BDSs) contribute importantly to morbidity after liver transplantation (LT). The purpose of this study was to estimate the clinical efficacy, safety, and long‐term results of percutaneous transhepatic cholangioscopic lithotripsy (PTCSL) in transplant recipients and to discuss underlying factors affecting the outcome.

Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients

Tommaso Di Maira, Angel Rubin, Lorena Puchades, Victoria Aguilera, Carmen Vinaixa, Maria Garcia, Nicola De Maria, Erica Villa, Rafael Lopez‐Andujar, Fernando San Juan, Eva Montalva, Judith Perez, Martin Prieto, Marina Berenguer – 30 March 2015 – Cardiovascular (CV) events represent major impediments to the long‐term survival of liver transplantation (LT) patients. The aim of this study was to assess whether the Framingham risk score (FRS) at transplantation can predict the development of post‐LT cardiovascular events (CVEs). Patients transplanted between 2006 and 2008 were included.

Liver‐targeted gene therapy: Approaches and challenges

Rajagopal N. Aravalli, John D. Belcher, Clifford J. Steer – 30 March 2015 – The liver plays a major role in many inherited and acquired genetic disorders. It is also the site for the treatment of certain inborn errors of metabolism that do not directly cause injury to the liver. The advancement of nucleic acid–based therapies for liver maladies has been severely limited because of the myriad untoward side effects and methodological limitations.

Selection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudins

Sharon E. Hopcraft, Matthew J. Evans – 29 March 2015 – Hepatitis C virus (HCV) cell entry is a complex, multistep process requiring numerous host cell factors, including the tight junction protein claudin‐1 (CLDN1). It is not known whether CLDN1 and the HCV glycoproteins physically interact. Therefore, the focus of this work was to study genetic interactions between CLDN1 and HCV. We used CRISPR technology to generate CLDN1 knockout (KO) Huh‐7.5 cells, which could not be infected by genotype 2a Jc1 HCV unless CLDN1 expression was restored.

Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients

Marta Milano, Alessio Aghemo, Rosellina Margherita Mancina, Janett Fischer, Paola Dongiovanni, Stella De Nicola, Anna Ludovica Fracanzani, Roberta D'Ambrosio, Marco Maggioni, Raffaele De Francesco, Silvia Fargion, Thomas Berg, Felix Stickel, Jochen Hampe, Stefano Romeo, Massimo Colombo, Luca Valenti – 29 March 2015 – Steatosis and inherited host factors influence liver damage progression in chronic hepatitis C (CHC). The transmembrane 6 superfamily member 2 (TM6SF2) gene E167K variant increases liver fat and risk of progressive steatohepatitis by interfering with lipoprotein secretion.

Subscribe to